

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

InVivoPlus anti-mouse CTLA-4 (CD152)

RRID:AB_10950184

Type: Antibody

Proper Citation

Bio X Cell Cat# BE0131, RRID:AB_10950184

Antibody Information

URL: http://antibodyregistry.org/AB_10950184

Proper Citation: Bio X Cell Cat# BE0131, RRID:AB_10950184

Target Antigen: CTLA-4 (CD152)

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization
Consolidation on 12/2021: AB_10950184, AB_2894807.

Antibody Name: InVivoPlus anti-mouse CTLA-4 (CD152)

Description: This monoclonal targets CTLA-4 (CD152)

Target Organism: mouse

Clone ID: clone 9H10

Antibody ID: AB_10950184

Vendor: Bio X Cell

Catalog Number: BE0131

Alternative Catalog Numbers: BP0131-5MG, BP0131-100MG, BE0131-100MG, BP0131-50MG, BE0131-25MG, BE0131-1MG, BP0131-25MG, BE0131-5MG, BE0131-50MG

Record Creation Time: 20250820T061247+0000

Record Last Update: 20250820T233248+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse CTLA-4 (CD152).

No alerts have been found for InVivoPlus anti-mouse CTLA-4 (CD152).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. Cell reports. Medicine, 6(6), 102141.

Akca U, et al. (2025) PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(12), 1908.

Cho NW, et al. (2025) T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNF?? Inflammation. Cancer immunology research, 13(2), 229.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer cell, 43(3), 428.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine, 6(11), 102446.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOA as a potential immunotherapy. Cell, 188(18), 5062.

Bachem A, et al. (2025) Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. Immunity, 58(11), 2799.

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell, 188(25), 7099.

Diers AR, et al. (2025) Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy. Cancer research communications, 5(2), 327.

Fan Y, et al. (2025) Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. *Cell metabolism*, 37(2), 514.

Guo C, et al. (2025) BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma. *Cell reports. Medicine*, 6(8), 102258.

Memon D, et al. (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. *Cancer cell*, 42(2), 209.

Liu J, et al. (2024) QDPR deficiency drives immune suppression in pancreatic cancer. *Cell metabolism*, 36(5), 984.

Mahadevan KK, et al. (2024) Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. *Science (New York, N.Y.)*, 384(6703), eadh4567.

Andreata F, et al. (2024) Therapeutic potential of co-signaling receptor modulation in hepatitis B. *Cell*, 187(15), 4078.

Bridges K, et al. (2024) Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance. *bioRxiv : the preprint server for biology*.

Bugno J, et al. (2024) Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4450.

Zhang Y, et al. (2024) A Novel Translational PET Imaging Approach to Quantifying Distal Tumor Immune Activation After Targeted Radiation Therapy and Checkpoint Blockade. *International journal of radiation oncology, biology, physics*, 118(5), 1217.

Rao Y, et al. (2024) The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma. *iScience*, 27(5), 109668.

Nayyar N, et al. (2024) CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(2), 420.